ENVALITH
生化学工業株式会社 logo

SEIKAGAKU CORPORATION

4548Prime MarketPharmaceuticals

生化学工業株式会社 logo
SEIKAGAKU CORPORATION4548

Governance

The company adopts a board of company auditors structure with five directors (two of whom are outside directors, and two independent officers). It has established a Nomination and Compensation Committee (comprising the President and two outside directors, with outside directors constituting the majority) as an advisory body to the Board of Directors, aiming to enhance transparent and fair decision-making and strengthen the oversight function.

Outside Director Ratio

40.0%

Nomination Committee

Established

Compensation Committee

Established

Risk Management

The Company has established a Risk Management Committee headed by the Representative Director and President as the Chief Risk Management Officer, and each department identifies and evaluates risks based on the

Shareholder Returns

The company's basic dividend policy is ¥26 per share annually, with dividend increases considered based on business performance and financial condition. The annual dividend for FY2026 (ending March 2026) is planned at ¥30 (interim ¥15 + year-end ¥15, payout ratio 111.2%), with the same ¥30 planned for FY2027 (ending March 2027). Share buybacks will also be considered as appropriate, taking into account the total shareholder return ratio.

Dividend Policy

The basic policy is an annual dividend of ¥26 per share, with dividend increases considered after taking into account business trends, financial condition, and other factors. Dividends are paid twice a year, as an interim dividend and a year-end dividend. The actual result for FY2026 (ending March 2026) is an annual dividend of ¥30 (interim ¥15, year-end ¥15, total dividend amount ¥1,638 million, payout ratio 111.2%). The forecast for FY2027 (ending March 2027) is also an annual dividend of ¥30 (interim ¥15, year-end ¥15, forecast payout ratio 72.8%). Share buybacks will also be considered as appropriate, taking into account future business development and the total shareholder return ratio.

Dividend

Paying

Share Buyback

Possible

Shareholder Benefits

None

ESG

The company has identified six materiality issues (creation of useful pharmaceuticals, stable supply, access to healthcare, governance, diverse human resources, and environmental consideration), and has set targets of a 46% reduction in CO2 emissions by 2030 (versus FY2017) and carbon neutrality by 2050. Against a target of raising the ratio of female managers to 25% or more by the end of March 2026, the actual figure stood at 16.7%; the male childcare leave uptake rate was 85.0%; and the company has obtained a CDP Climate Change score of B.

Last updated: June 18, 2026